🔗 Share this article

While the United States proceeds with historic changes to its immunization recommendations, one figure has emerged unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by questioning Covid shots during the pandemic and has concentrated on possible fatalities following COVID-19 immunization in her short tenure at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Vaccine Schedule

Health officials had intended to unveil radical revisions to the pediatric vaccine schedule recently, aligning the US with the Danish immunization schedule, sources say – a significant shift that would place the US at odds with many the global community with little proof for benefit. This reveal has been postponed until the next year.

Rather than the director of the vaccine center, Tracy Beth Høeg is scheduled to address the audience at the event. She was just designated acting director of the FDA’s CDER, the fifth appointee to run the division this year.

Consolidating Power at the Agency

This interim role might represent a strengthened alliance between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a increased emphasis upon dismantling previously authorized immunizations at the FDA.

The new acting director has frequently advocated for discontinuing specific pediatric immunization guidelines in the US so as to align more similar to the Danish model, a nation with universal health coverage and a number of inhabitants roughly the size of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on vaccination policy – typically the responsibility of Prasad, head of the FDA’s vaccine center – instead of pharmaceutical oversight.

Doubts Over Qualifications

Dr. Høeg has no obvious background in pharmaceutical research, oversight or administrative roles, which has been customary for past heads of the biologics center. She has served at the FDA as a key advisor to the agency head and CBER since earlier this year.

“She appears not to have any of the qualifications” for running the CDER, remarked Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in managing a major agency. She lacks background in pharmaceutical oversight.”

Past commissioners of the center would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that former directors who headed CBER have had.”

CDER has an vast portfolio at the agency, she emphasized.

“Many people just zeroes in on the innovative therapies, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and other areas, and every single one have to be managed,” Dr. Woodcock said. “The responsibility you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a substantial management aspect to the job, which oversees over 5,000 personnel. “It’s a massive administrative position, if you execute it properly,” Woodcock added.

Official Statement and Controversial Programs

When asked about inquiries about Høeg’s qualifications and whether this selection signifies more teamwork among agency officials on immunizations, a representative responded that the “concerns rely on inaccurate presumptions”.

“Her experience aligns with the duties of her position,” the representative explained, noting the months Dr. Høeg spent counseling the agency head on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a controversial rapid drug-approval program that reportedly worried her former heads. “How are these medications being chosen for this expedited pathway? Who takes the choices?” Dr. Howard questioned. “There is a lot of confidentiality happening at the FDA right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards laxer regulations of most medications, except for immunizations.”

Established History on Vaccines

With immunizations, Høeg has a more documented, if concerning, track record, some experts have noted. She published a analysis using unverified crowd-sourced reports to estimate the rate of heart inflammation following Covid vaccination. She counseled the state of Florida top health official Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are more dangerous than they are.

Part of her “policy goals” for the current federal leadership encompassed revising guidelines for novel immunizations and halting “optional” vaccines, she stated post-election on a podcast. At the FDA, Høeg has reportedly proposed excluding teenage boys from receiving COVID-19 vaccines.

“She’s an complete true believer who begins with her conclusions and reverse-engineers to retrofit the evidence in a very deceptive, untruthful manner,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg aligned with other dissenters, {like|